NEJM RCT: Setmelanotide Cuts BMI 17% in Hypothalamic Obesity After Brain Tumors

The double-blind trial randomized 81 patients to setmelanotide and 39 to placebo. Participants had hypothalamic lesions from tumors or treatment, prior GLP-1 nonresponse, and mean adult BMI of 41.8. Setmelanotide targets MC4R signaling disrupted by hypothalamic injury, restoring satiety and energy expenditure pathways that GLP-1 agonists bypass.

Net 20% BMI difference translated to roughly 24 kg loss for a 170 cm adult. Skin hyperpigmentation, nausea, and headache occurred in 88%, yet 95% elected open-label continuation. This outcome isolates a neuroendocrine mechanism rarely addressed in standard obesity trials focused on caloric or incretin pathways.

Prior observational cohorts documented 50-70% of craniopharyngioma survivors developing intractable hypothalamic obesity unresponsive to lifestyle or GLP-1 agents. Setmelanotide approval by FDA and EMA now creates a labeled indication for this etiology, prompting re-evaluation of post-treatment endocrine surveillance protocols.

Next steps include planned 24-month extension data and pediatric subgroup analyses to assess growth and bone-density effects. Registries tracking cardiovascular events will determine whether the BMI reduction alters hard endpoints beyond surrogate metabolic markers.